KPV (Lys-Pro-Val) is a tripeptide corresponding to the C-terminal amino acids 11-13 of alpha-melanocyte stimulating hormone (alpha-MSH), a 13-amino acid peptide derived from proopiomelanocortin (POMC). Alpha-MSH is well-established as a potent endogenous anti-inflammatory mediator, and research has demonstrated that much of its anti-inflammatory activity is retained within this minimal three-amino acid C-terminal fragment.
The key finding that distinguishes KPV from its parent hormone is that its anti-inflammatory mechanism appears to be independent of melanocortin receptors (MC1R through MC5R). Unlike full-length alpha-MSH, KPV does not bind to melanocortin receptors at physiologically relevant concentrations. Instead, KPV is transported into cells via PepT1 (SLC15A1), an H+-coupled oligopeptide transporter normally expressed in the small intestine and upregulated in the colon during inflammatory bowel disease. Once inside the cell, KPV inhibits NF-kB activation and MAP kinase inflammatory signaling pathways at nanomolar concentrations.
This PepT1-mediated uptake mechanism is particularly significant because PepT1 expression increases during intestinal inflammation, meaning that inflamed intestinal tissue may preferentially absorb KPV. This creates a potential for targeted delivery to the site of pathology, which is an unusual and advantageous pharmacological property for an anti-inflammatory agent.
Critical evidence context: As of 2026, there are zero published human clinical trials on KPV as an isolated tripeptide. All published efficacy data comes from in vitro cell culture studies and murine models of colitis (DSS-induced and TNBS-induced). The preclinical evidence is promising but has not been validated in human subjects.
| Weeks | Dosage | Syringe units (U-100) |
|---|---|---|
| Week 1 | 0.2 mg | 6 units0.06 mL |
| Week 2 | 0.3 mg | 9 units0.09 mL |
| Week 3 | 0.4 mg | 12 units0.12 mL |
| Weeks 4–8 | 0.5 mg | 15 units0.15 mL |
FrequencyOnce daily, subcutaneous.
For review — no human dosing exists. KPV's evidence is cell culture and rodent colitis models using oral, rectal and nanoparticle preparations; the subcutaneous rows in the chart follow a circulated research protocol. The concentration strip above the chart is calculated from the vial and water volume and is correct.
Unverified — no human study establishes any frequency for KPV.
KPV is the three-amino-acid tail of alpha-MSH, and the work behind it is preclinical: cell culture and rodent models of colitis, delivered by mouth, rectally or inside nanoparticles designed to reach the gut wall. None of those is an injection, there is no human trial and no established amount, so the subcutaneous schedule charted here is flagged for review rather than presented as dosing. The delivery detail matters — much of the rodent evidence depends on getting KPV to inflamed intestinal tissue, which a subcutaneous injection does not do in the same way. Athena lists one strength: a 10 mg vial made up with 3 mL gives about 3.33 mg/mL, so the schedule runs from 6 units at the 0.2 mg first step to 15 units at the 0.5 mg final step, and every row fits inside one 50-unit syringe.
What this evidence establishes. No human dosing exists for KPV. The work behind it is preclinical — cell culture and rodent models of colitis, using oral, rectal and nanoparticle-delivered preparations rather than injection. There is no human trial, no established dose, and no established frequency. The table below is reconstitution arithmetic only.
For educational and laboratory research purposes only. It does not provide medical advice, dosing recommendations, or instructions for human or veterinary use. Syringe units assume a U-100 syringe, on which 1 mL is 100 units and a 50-unit syringe holds 0.5 mL.
KPV's anti-inflammatory effects operate through intracellular pathways accessed via the PepT1 transporter, distinguishing it from classical melanocortin receptor-mediated signaling:
Transported into intestinal epithelial and immune cells via the H+-coupled oligopeptide transporter PepT1, which is upregulated during intestinal inflammation
Suppresses nuclear translocation of NF-kB at nanomolar concentrations, blocking transcription of pro-inflammatory cytokine genes (TNF-alpha, IL-1beta, IL-6)
Inhibits MAP kinase inflammatory signaling cascades (ERK, p38, JNK), reducing downstream inflammatory mediator production
Promotes wound healing in intestinal epithelial layers and supports barrier integrity in cell culture wound-healing assays (ECIS technology)
Reduces pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha, IFN-gamma) without altering anti-inflammatory IL-10 levels, suggesting targeted immune modulation
Anti-inflammatory activity is retained in MC1R-deficient mice, confirming that KPV acts through intracellular pathways independent of classical melanocortin receptor signaling
Critical caveat: KPV does not suppress overall immune function the way corticosteroids or broad immunosuppressants do. It dampens inflammatory signaling intensity rather than broadly altering immune balance. However, this distinction has been demonstrated only in preclinical models, not in human studies.
Because KPV has zero published human clinical trials, the safety profile is derived entirely from preclinical data (cell culture and animal models). The following assessments are theoretical and based on known mechanisms:
| Condition / Factor | Risk Level | Rationale |
|---|---|---|
| Active infection | MODERATE (theoretical) | NF-kB suppression could theoretically impair acute immune responses needed to fight active infections. Not studied in humans. |
| Immunosuppressive therapy | MODERATE (theoretical) | Additive immune pathway suppression may occur. No drug interaction studies have been conducted. |
| Pregnancy / breastfeeding | UNKNOWN | No reproductive toxicology data exists for KPV. Standard precaution for unstudied compounds. |
| GI malignancy | MODERATE (nuanced) | In colitis-associated cancer models, KPV reduced tumors. In genetic cancer models without inflammation, no tumor effect. Complexity warrants caution. |
| Melanocortin system disorders | LOW (unlikely) | KPV does not appear to bind melanocortin receptors at meaningful concentrations. Unlike alpha-MSH, it should not affect pigmentation or melanocortin-mediated pathways. |
| Injection site reactions | LOW (preclinical) | No significant local reactions reported in animal studies. No human injection data published. |
| Oral tolerability | LOW (preclinical) | Animal studies show oral KPV is well-tolerated without toxic effects at standard research doses. |
| Long-term safety | UNKNOWN | No long-term safety data exists in any species. Effects of chronic NF-kB modulation via KPV are unstudied. |
| Drug interactions | UNKNOWN | Zero drug interaction studies have been conducted. Potential interactions with immunosuppressants, biologics, and other anti-inflammatory agents are unknown. |
| Human safety data | ABSENT | Zero published human clinical trials. All safety assessments are extrapolated from preclinical models. This is a fundamental limitation. |
FDA: KPV is not FDA-approved for any indication. It has not been submitted for IND (Investigational New Drug) application as an isolated tripeptide.
Clinical Evidence: Zero published human clinical trials exist for KPV as an isolated compound. The entire evidence base consists of in vitro cell culture studies and murine models of colitis. This is a preclinical compound, not a clinically validated therapeutic.
Availability: KPV is available from peptide suppliers and is used in integrative medicine clinics via subcutaneous injection and oral capsules. The clinical evidence base is still developing relative to adoption.
Key distinction: KPV's preclinical data is genuinely interesting. The PepT1 transport mechanism, NF-kB inhibition at nanomolar concentrations, and oral bioactivity in animal models represent real scientific findings published in peer-reviewed journals (Gastroenterology, Molecular Therapy). However, interesting preclinical data is fundamentally different from clinical evidence of safety and efficacy in humans. The gap between the two has not been bridged.
Answer these compound-specific questions to evaluate your understanding of KPV's evidence base, mechanism, and limitations.
This profile is for educational and research purposes only. It is not medical advice, and nothing on it is a protocol, a recommendation, or an instruction for use in a person or an animal.
Athena Peptides Education does not prescribe, sell, or recommend any compound. Compounds discussed here are for laboratory research only and are not for human consumption. Always consult a qualified physician before making any decision about your health.